FindTrial
Sign In

A portable microchip platform for various respiratory virus nucleic acids testing at the point of care

A portable microchip platform for various respiratory virus nucleic acids testing at the point of care

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036697
Enrollment
Unknown
Registered
2020-08-24
Start date
2021-09-01
Completion date
Unknown
Last updated
2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory virus infection

Interventions

Gold Standard:Rt-pcr and Sanger sequencing are the gold standards
Index test:Loop-mediated&#32
isothermal&#32
amplification
&#32
RI-PCR
Sanger&#32
sequencing,&#32
agarose&#32
gel&#32
electrophoresis

Sponsors

Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)It meets the clinical diagnostic criteria of upper respiratory tract virus infection; 2)The patients were between 3 and 70 years old; 3)Patients who need to make the COVID-19 nucleic acid test.

Exclusion criteria

Exclusion criteria: 1) Patients with severe heart disease; 2) Patients with abnormal structure of nasopharynx.

Design outcomes

Primary

MeasureTime frame
sensitivity;—

Secondary

MeasureTime frame
specificity;—

Countries

China

Contacts

Public ContactLi min

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

ruth_limin@126.com+86 13918363998

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026